RNAU1-18: A Versatile RNA-protein Complex Involved in Various Cellular Processes

Target Name: RNVU1-18

NCBI ID: G26863

RNVU1-18

Other Name(s): RNU1P1 | U1.15 | RNA, variant U1 small nuclear 18 | RNU1-25 | U1P15 | RNU1-5 | vU1.18 | RNU1-25P | U1P101 | RNU1P9

RNAU1-18: A Versatile RNA-protein Complex Involved in Various Cellular Processes

The RNA-protein complex (RNA-protein) is a ubiquitous entity in all cells, and it plays a crucial role in various cellular processes. One of the well-known RNA-protein complexes is the nucleolin binding partner RNAU (RNU) family, which consists of different subfamilies, including RNU1-18 (RNU1P1). RNU1-18 is a protein that was first identified in the nucleoplasm using Southern blotting techniques, and it has been shown to interact with various RNA molecules, including rRNA, snRNA , and microRNA (miRNA) species.

RNAU1-18 is a 21-kDa protein that contains 108 amino acid residues. It has a characteristic imidazole ring structure and is composed of two distinct domains: an N-terminal domain and a C-terminal domain. The N-terminal domain is rich in conserved features, such as a leucine amino acid residue, a glutamic acid amino acid residue, and a lysine amino acid residue, which are all involved in protein-protein interactions. The C-terminal domain is also conserved and is involved in the formation of a hydrogen bond with the N-terminal domain.

RNAU1-18 has been shown to play a critical role in various cellular processes, including cell growth, apoptosis, and translation. One of the well-known functions of RNU1-18 is its ability to interact with small RNA species, such as miRNA and rRNA. miRNA, a small non-coding RNA molecule, plays a crucial role in post-transcriptional regulation by targeting mRNAs for degradation. RNU1-18 has been shown to interact with miRNA species, including miR-18a, miR-202, and miR -21, and it has been shown to regulate the translation of miRNA precursors into functional miRNAs.

In addition to its role in miRNA regulation, RNU1-18 has also been shown to play a critical role in the regulation of alternative splicing. Alternative splicing is a process by which the cell removes non-coding exons from the pre-mRNA and uses the remaining exons to generate a functional RNA product. RNU1-18 has been shown to interact with the protein ExonicOrder (XO), which is a component of the splicing machinery. By interacting with XO, RNU1-18 has been shown to regulate the exonic inclusion of exons in the final RNA product.

RNAU1-18 has also been shown to play a critical role in the regulation of cell growth and apoptosis. The growth and apoptosis of cells are highly regulated processes that are tightly controlled by various signaling pathways. RNU1-18 has been shown to interact with several signaling pathways, including the TGF-β pathway and the PI3K/Akt pathway.

TGF-β is a well-known signaling pathway that regulates cell growth and apoptosis. TGF-β signaling is dependent on the interaction between the TGF-β receptor and the Smad protein. RNU1-18 has been shown to interact with the TGF-β receptor and has been shown to regulate the translation of TGF-β signaling proteins into the cell.

The PI3K/Akt signaling pathway is another well-known signaling pathway that regulates cell growth and apoptosis. PI3K is a protein that plays a critical role in the regulation of cell membrane rigidity and is involved in the production of pro-inflammatory cytokines. Akt is a protein that is involved in the regulation of cell growth and apoptosis by phosphate

Protein Name: RNA, Variant U1 Small Nuclear 18

The "RNVU1-18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNVU1-18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets